INVESTORS
Engrail Therapeutics is a clinical-stage pharmaceutical company dedicated to delivering transformational therapies to patients with devastating disorders of the nervous system. Our deep, differentiated pipeline includes compounds in clinical development for focal epilepsy and generalized anxiety disorder.
We invite you to learn more about our exciting and diverse neuroscience pipeline, experienced leadership team, unique scientific approach, and flexible transaction model.
MEDIA
Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy
SAN DIEGO – June 7, 2022 – Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, has announced positive results from a phase 1b clinical trial of ENX-101, a subtype-selective GABA-A positive allosteric modulator (PAM). The phase 1b clinical trial data were presented on June 6, 2022, at the 2022 Epilepsy Pipeline Conference in Santa Clara, California.
Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement for Elesclomol in Disorders of Mitochondrial Copper Metabolism
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS), today announced that they have entered into a license agreement which grants Engrail worldwide exclusive rights to intellectual property around the use of elesclomol for disorders of mitochondrial copper metabolism.
Engrail Therapeutics Extends Series A Financing to $64 Million
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
Engrail Therapeutics Acquires NeuroCycle Therapeutics
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) today announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation. The acquisition strengthens Engrail’s presence in the GABA-A space and provides a strong platform for initiation of clinical trials with multiple assets in 2021. “We believe Engrail represents the ideal company to carry on the work NeuroCycle started given their focus and experience in the GABA-A space.
Engrail Therapeutics Strengthens Leadership Team With Key Executive Appointments and Expands Board of Directors
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced two key executive appointments. Kimberly Vanover, Ph.D. has been named chief scientific officer, leading the building and advancement of the Company’s pipeline. Eve Taylor, Ph.D. has been named vice president, clinical development, overseeing all facets of Engrail’s clinical development programs and operations.
Engrail Therapeutics Raises $32 Million in Series A Financing
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company) today announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led the round. The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.